Clinical trials
PALB2 Gene Mutation clinical trials
Below are recruiting palb2 gene mutation clinical trials, each written for real people, not researchers. We’re tracking 12 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05420064Recruiting
Help with family cancer gene testing and unclear results
This trial helps people and their doctors understand and act on genetic test results, including when results are uncertain. It tests whether a structured approach improves who gets tested in families and helps patients and primary care providers stay up-to-date.
Basking Ridge, New JerseyAges 25 years+ - NCT06177171RecruitingPhase 1
Olaparib and ASTX727 for DNA repair-deficient cancers
This trial tests a combination of two drugs—olaparib (a PARP inhibitor) and ASTX727 (a DNA hypomethylating agent)—for people whose cancers have a specific DNA repair flaw. The goal is to see if this combination can shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT05097274Recruiting
PET-CT scan for men with prostate cancer and a DNA repair mutation
This study uses a special scan (FCH-PET-CT) to help doctors see prostate cancer more clearly in men who have a known gene change involved in DNA repair. It’s meant to improve staging and assessment, especially around when imaging is needed.
London, Sutton, SurreyAges 18 years+ - NCT05694715RecruitingPhase 1
Test combo treatment for cancers with DNA repair gene mutations
This Phase 1 study tests a combination of medicines (including niraparib and irinotecan) for advanced solid tumors that have specific DNA repair gene changes, such as BRCA1/2 or related defects. It aims to see whether the treatment can shrink tumors and is safe enough to continue studying.
San Francisco, CaliforniaAges 18 years+ - NCT05129605Recruiting
Prostate cancer genetic risk screening study for men
This study looks at your personal and family risk for prostate cancer and helps decide who should have extra screening like MRI. It may help you find cancer earlier if you are at higher genetic risk.
Boston, MassachusettsAges 35–74 - NCT04150042RecruitingPhase 1
Test of chemotherapy plus your own stem cells for metastatic cancer
This Phase 1 trial tests a treatment approach using standard chemotherapy along with stem cells taken from you to treat metastatic pancreatic or breast cancer. It is mainly designed to check safety and find the best way to give the treatment, and it may offer an option for people whose cancer has spread.
Boston, MassachusettsAges 18 years+ - NCT05761470RecruitingPhase 2
Test before-surgery cancer treatment for breast tumors with DNA repair gene changes
This trial tests a combination of medications given before surgery (neoadjuvant therapy) for early breast cancer. It is designed for tumors with certain “DNA repair” gene mutations and aims to improve treatment results while shrinking or controlling the cancer.
Guangzhou, GuangdongAges 18–75 - NCT02000089RecruitingPhase 3
Pancreas screening study for people at high cancer risk
This Phase 3 study tests a structured plan for checking the pancreas early in people with a higher-than-usual risk of pancreatic cancer. The goal is to find changes sooner, when treatment may be easier.
New Haven, ConnecticutAges 18 years+ - NCT07498829Recruiting
Cancer risk genetic testing for people with female organs
This study offers free genetic testing to women, trans men, and non-binary people (with female reproductive organs) who have not had previous testing for certain cancer-related genes. It aims to find people at higher risk for cancer so they can take steps to prevent it or catch it early.
LondonAges 18 years+ - NCT03786796RecruitingPhase 2
Olaparib for metastatic kidney cancer with specific DNA repair gene changes
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
Baltimore, MarylandAges 18–120 - NCT05222971RecruitingPhase 2
Olaparib, with or without immunotherapy, for DNA-repair biliary cancer
This Phase 2 study tests olaparib (a targeted anti-cancer pill) alone or with durvalumab (an immunotherapy) for biliary tract cancers that have specific DNA repair gene changes. It’s for people whose cancer has continued after standard platinum chemotherapy, aiming to slow or control the disease.
SeoulAges 19 years+ - NCT04890613RecruitingPhase 1
CX-5461 for cancers with BRCA or HRD gene changes
This Phase 1 trial tests CX-5461, a new cancer medicine, in people with certain solid tumors that have BRCA1/2 or related “HRD” gene mutations. The goal is to find out how the drug works, what dose is tolerable, and whether it can help shrink tumors.
Santa Monica, CaliforniaAges 18 years+
Hear when a new PALB2 Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for palb2 gene mutation?
- Yes. Clin2 currently lists 12 recruiting palb2 gene mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a palb2 gene mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a palb2 gene mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.